A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Registration Number
- NCT01030783
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Brief Summary
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
- Detailed Description
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
Subjects will be randomized (1:1) to treatment with tivozanib or sorafenib and stratified by geographic region (North America/Western Europe, Central/Eastern Europe, or rest of the world); number of prior treatments (0 or 1); and number of metastatic sites/organs involved (1 or ≥ 2).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 517
- ≥ 18-years of age.
- Subjects with recurrent or metastatic RCC.
- Subjects must have undergone prior nephrectomy (complete or partial) for excision of the primary tumor.
- Histologically or cytologically confirmed RCC with a clear cell component (subjects with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, mixed tumor containing predominantly sarcomatoid cells, and unclassified RCC are excluded).
- Measurable disease per the RECIST criteria Version 1.0.
- Treatment naïve subjects or subjects who have received no more than one prior systemic treatment (immunotherapy, including interferon-alfa or interleukin-2 based therapy, chemotherapy, hormonal therapy or an investigational agent) for metastatic RCC. Postoperative or adjuvant systemic therapy will not be counted as a prior therapy unless recurrence is detected within 6 months of completion of treatment, in which case it will be counted as a prior therapy for metastatic disease.
- ECOG performance status of 0 or 1, and life expectancy ≥ 3 months.
- If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
- Ability to give written informed consent and comply with protocol requirements.
- Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib, etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent targeting the VEGF pathway.
- Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus, everolimus, etc)
- Primary CNS malignancies or CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis have been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery).
- Any hematologic abnormalities (as noted in the protocol).
- Any serum chemistry abnormalities (as noted in the protocol).
- Significant cardiovascular disease.
- Non-healing wound, bone fracture, or skin ulcer.
- Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug.
- Serious/active infection or infection requiring parenteral antibiotics.
- Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.
- Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug.
- Significant bleeding disorders within 6 months prior to administration of first dose of study drug.
- Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for >2 years.
- Pregnant or lactating females.
- History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant.
- Life-threatening illness or organ system dysfunction compromising safety evaluation.
- Requirement for hemodialysis or peritoneal dialysis.
- Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib or sorafenib, major resection of the stomach or small bowel, or gastric bypass procedure.
- Psychiatric disorder or altered mental status precluding informed consent or necessary testing.
- Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study for at least 90 days after the last dose of drug. All fertile male and female subjects and their partners must agree to use a highly effective method of contraception (including their partner). Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description tivozanib (AV-951) tivozanib (AV-951) - sorafenib Sorafenib -
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks. Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib Every 8 weeks from date of randomization until disease progression Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0).
Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib Date of randomization to date of death Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization.
Safety and Tolerability of Tivozanib and Sorafenib From start of treatment therapy to completion of treatment therapy, an average of 11 months Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF.
Pharmacokinetics (Serum Concentrations) of Tivozanib Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28 Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL).
To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib At Day 1 of each 28 day cycle throughout the course of the study, for an average of 11 months per subject The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit.
Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib Assessed every 8 weeks from date of randomization until date of progression Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause.
Trial Locations
- Locations (86)
Site 155
🇮🇳Jaipur, Rajasthan, India
Site 191
🇮🇳Jaipur, Rajasthan, India
Site 152
🇮🇳Vellore, Tamil Nadu, India
Site 481
🇷🇸Belgrade, Serbia
Site 190
🇮🇳Patna, Bihar, India
Site 484
🇷🇸Sremska Kamenica, Serbia
Site 157
🇮🇳Hyderabad, Andhra Pradesh, India
Site 159
🇮🇳Pune, Maharashtra, India
Site 122
🇨🇱Santiago, Chile
Site 154
🇮🇳Delhi, India
Site 480
🇷🇸Belgrade, Serbia
Site 156
🇮🇳Ahmedabad, Gujarat, India
Site 150
🇮🇳Kolkata, West Bengal, India
Site 158
🇮🇳Lucknow, Uttar Pradesh, India
Site 185
🇺🇸Los Angeles, California, United States
Site 102
🇦🇷Sante Fe, Argentina
Site 187
🇺🇸Dallas, Texas, United States
Site 404
🇧🇬Sofia, Bulgaria
Site 403
🇧🇬Plovdiv, Bulgaria
Site 400
🇧🇬Sofia, Bulgaria
Site 110
🇨🇦Montréal, Quebec, Canada
Site 133
🇫🇷Saint Herblain Cedex, France
Site 130
🇫🇷Marseille, France
Site 421
🇭🇺Kaposvár, Hungary
Site 424
🇭🇺Szombathely, Hungary
Site 160
🇮🇹Arezzo, Italy
Site 161
🇮🇹Pavia, Italy
Site 162
🇮🇹Roma, Italy
Site 434
🇵🇱Bydgoszcz, Poland
Site 432
🇵🇱Bialystok, Poland
Site 431
🇵🇱Gdansk, Poland
Site 433
🇵🇱Poznan, Poland
Site 436
🇵🇱Warsaw, Poland
Site 435
🇵🇱Olsztyn, Poland
Site 430
🇵🇱Warsaw, Poland
Site 444
🇷🇴Brasov, Romania
Site 492
🇺🇦Dniproperovsk, Ukraine
Site 441
🇷🇴Bucharest, Romania
Site 440
🇷🇴Bucharest, Romania
Site 443
🇷🇴Bucharest, Romania
Site 442
🇷🇴Timisoara, Romania
Site 451
🇷🇺Chelyabinsk, Russian Federation
Site 455
🇷🇺Ekaterinburg, Russian Federation
Site 468
🇷🇺Ioshkar Ola, Russian Federation
Site 452
🇷🇺Kazan, Russian Federation
Site 454
🇷🇺Moscow, Russian Federation
Site 461
🇷🇺Moscow, Russian Federation
Site 462
🇷🇺Moscow, Russian Federation
Site 456
🇷🇺Obninsk, Russian Federation
Site 460
🇷🇺Moscow, Russian Federation
Site 467
🇷🇺Omsk, Russian Federation
Site 450
🇷🇺Nizhny Novgorod, Russian Federation
Site 482
🇷🇸Belgrade, Serbia
Site 457
🇷🇺Rostov-on-Don, Russian Federation
Site 483
🇷🇸Nis, Serbia
Site 491
🇺🇦Chernihiv, Ukraine
Site 498
🇺🇦Dnipropetrovsk, Ukraine
Site 493
🇺🇦Donetsk, Ukraine
Site 496
🇺🇦Donetsk, Ukraine
Site 490
🇺🇦Ivano-Frankivsk, Ukraine
Site 494
🇺🇦Kharkiv, Ukraine
Site 497
🇺🇦Uzhhorod, Ukraine
Site 495
🇺🇦Zaporizhia, Ukraine
Site 459
🇷🇺Ufa, Republic Of Bashkortostan, Russian Federation
Site 453
🇷🇺Moscow, Russian Federation
Site 180
🇺🇸Gainesville, Florida, United States
Site 184
🇺🇸Orlando, Florida, United States
Site 182
🇺🇸Minneapolis, Minnesota, United States
Site 186
🇺🇸New York, New York, United States
Site 401
🇧🇬Varna, Bulgaria
Site 402
🇧🇬Veliko Tarnovo, Bulgaria
Site 121
🇨🇱La Reina, Santiago De Chile, Chile
Site 123
🇨🇱Temuco, Chile
Site 411
🇨🇿Prague 8, Czechia
Site 422
🇭🇺Pécs, Hungary
Site 423
🇭🇺Budapest, Hungary
Site 151
🇮🇳Nashik, Maharashtra, India
Site 153
🇮🇳Pune, Maharashtra, India
Site 458
🇷🇺Moscow, Russian Federation
Site 463
🇷🇺Pyatigorsk, Russian Federation
Site 465
🇷🇺St. Petersburg, Russian Federation
Site 466
🇷🇺St. Petersburg, Russian Federation
Site 464
🇷🇺Yaroslavi, Russian Federation
Site 170
🇬🇧Cambridge, United Kingdom
Site 173
🇬🇧Ipswich, United Kingdom
Site 172
🇬🇧Leicester, United Kingdom